India considering attaching a compulsory license label to ribociclib

11 January 2023

The Kerela High Court in India has directed the Department for Promotion of Industry and Internal Trade to consider compulsory licensing of breast cancer drug ribociclib.

Ribociclib is manufactured by Swiss pharma giant Novartis (NOVN: VX. Available in India as Kryxana (Kisqali in most other countries), it costs $712.63 per month and is among three drugs prescribed for late-stage luminal A breast cancer. The other two drugs available in India are Pfizer’s (NYSE: PFE) palbociclib and Eli Lilly’s (NYSE: LLY) (pemetrexed), and were also under patent and prohibitively expensive.

Recently, the Kerala High Court had taken suo moto cognisance of the unaffordability of the drug after the tragic death of the petitioner who had earlier urged the Indian government to use the patent act's levers to curtail the escalating cost of the life-saving treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK